Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion

Vox Sanguinis

Volumn 106, Issue 4, 2014, Pages 307-315

  Feys, H B ^a   Van Aelst, B ^a   Devreese, K ^b   Devloo, R ^a   Coene, J ^c   Vandekerckhove, P ^c   Compernolle, V ^a,c  

^a Transfusion Research Center Belgian Red Cross Flanders   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Rode Kruis Vlaanderen   (Belgium)

Author keywords

Pathogen inactivation; Plasma; Reactive oxygen species

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; CARBONYL DERIVATIVE; DISSOLVED OXYGEN; FIBRINOGEN; METHYLENE BLUE; PLASMA PROTEIN; REACTIVE OXYGEN METABOLITE; RIBOFLAVIN; SUPEROXIDE; SUPEROXIDE DISMUTASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; OXYGEN; PHOTOSENSITIZING AGENT;

ARTICLE; BLOOD FILTRATION; BLOOD STORAGE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; MOLECULAR WEIGHT; NITROBLUE TETRAZOLIUM TEST; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHOTOCHEMISTRY; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; RIBOFLAVIN PATHOGEN REDUCTION TECHNOLOGY; SPARGING; ULTRAVIOLET RADIATION; WESTERN BLOTTING; BLOOD; BLOOD COMPONENT THERAPY; BLOOD SAFETY; BLOODBORNE BACTERIUM; CHEMISTRY; DISINFECTION; DRUG EFFECTS; HUMAN; PLASMA; PROCEDURES; RADIATION RESPONSE;

ADAM PROTEINS; BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; BLOOD PROTEINS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; DISINFECTION; HUMANS; OXIDATION-REDUCTION; OXYGEN; PHOTOSENSITIZING AGENTS; PLASMA; PROTEIN CARBONYLATION; RIBOFLAVIN; SUPEROXIDES; ULTRAVIOLET RAYS;

EID: 84898816839     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12106     Document Type: Article

References (34)

1. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al.: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11-28
2. Dodd RY: Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159:135-142
3. Allain JP, Stramer SL, Carneiro-Proietti AB, et al.: Transfusion-transmitted infectious diseases. Biologicals 2009; 37:71-77
4. Pelletier JP, Transue S, Snyder EL: Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19:205-242
5. Hornsey VS, Drummond O, Young D, et al.: A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001; 11:31-36
6. Ciaravino V, McCullough T, Cimino G, et al.: Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang 2003; 85:171-182
7. Lin L, Cook DN, Wiesehahn GP, et al.: Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-435
8. Ruane PH, Edrich R, Gampp D, et al.: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885
9. Kumar V, Lockerbie O, Keil SD, et al.: Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80:15-21
10. Smith J, Rock G: Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010; 50:926-931
11. Benjamin RJ, McLaughlin LS: Plasma components: properties, differences, and uses. Transfusion 2012; 52(Suppl. 1):9S-19S
12. Mintz PD, Bass NM, Petz LD, et al.: Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107:3753-3760
13. Bartelmaos T, Chabanel A, Leger J, et al.: Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013; 53:1335-1345
14. Coene J, Devreese K, Sabot B, et al.: Paired analysis of plasma proteins and coagulant capacity following treatment with three methods of pathogen reduction. Transfusion 2013; doi: 10.1111/trf.12460 [Epub ahead of print]
15. Bihm DJ, Ettinger A, Buytaert-Hoefen KA, et al.: Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C. Vox Sang 2010; 98:108-115
16. Kokame K, Nobe Y, Kokubo Y, et al.: FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100
17. Anderson PJ, Kokame K, Sadler JE: Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 2006; 281:850-857
18. Crawley JT, Lam JK, Rance JB, et al.: Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105:1085-1093
19. Gibson SL, Cohen HJ, Hilf R: Evidence against the production of superoxide by photoirradiation of hematoporphyrin derivative. Photochem Photobiol 1984; 40:441-448
20. Dalle-Donne I, Rossi R, Giustarini D, et al.: Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003; 329:23-38
21. Feys HB, Vandeputte N, Palla R, et al.: Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:2053-2062
22. Levine RL, Wehr N, Williams JA, et al.: Determination of carbonyl groups in oxidized proteins. Methods Mol Biol 2000; 99:15-24
23. Del Río-Garma J, Alvarez-Larrán A, Martínez C, et al.: Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143:39-45
24. Moake JL: Thrombotic thrombocytopenic purpura: the systemic clumping "plague". Annu Rev Med 2002; 53:75-88
25. Speck WT, Chen CC, Rosenkranz HS: In vitro studies of effects of light and riboflavin on DNA and HeLa cells. Pediatr Res 1975; 9:150-153
26. -) mechanisms. Toxicol Lett 1985; 26:211-217
27. Niki E: Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 2009; 47:469-484
28. Suzuki YJ, Carini M, Butterfield DA: Protein carbonylation. Antioxid Redox Signal 2010; 12:323-325
29. Singh R, Barden A, Mori T, et al.: Advanced glycation end-products: a review. Diabetologia 2001; 44:129-146
30. Maisch T, Baier J, Franz B, et al.: The role of singlet oxygen and oxygen concentration in photodynamic inactivation of bacteria. Proc Natl Acad Sci USA 2007; 104:7223-7228
31. Dardare N, Platz MS: Binding affinities of commonly employed sensitizers of viral inactivation. Photochem Photobiol 2002; 75:561-564
32. Kasai H, Yamaizumi Z, Berger M, et al.: Photosensitized formation of 7, 8-dihydro-8-oxo-2'-deoxyguanosine (8-hydroxy-2'-deoxyguanosine) in DNA by riboflavin: a nonsinglet oxygen-mediated reaction. J Am Chem Soc 1992; 114:9692-9694
33. Johnson L, Marks D: Mirasol pathogen reduction technology modulates platelet oxidative stress [abstract]. Vox Sang 2013; 105:65-299 Abstract P-195.
34. Kilkson H, Holme S, Murphy S: Platelet metabolism during storage of platelet concentrates at 22 degrees C. Blood 1984; 64:406-414